Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTARES PHARMA, INC.

(ATRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ANTARES PHARMA, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

08/05/2021 | 08:10am EDT

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2021, Antares Pharma, Inc. (the "Company") issued a press release announcing its operating and financial results for the second quarter ended June 30, 2021. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific references in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
  No.     Description

99.1        Press Release issued by Antares Pharma, Inc., dated August 5, 2021

104       Cover Page Interactive Data File (embedded within the Inline XBRL document)





--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ANTARES PHARMA, INC.
10/19ANTARES PHARMA : Enters into exclusive license agreement with lipocine for tlando in u.s.
AQ
10/19LIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO
AQ
10/18LIPOCINE : Signs Deal with Antares Pharma for Commercialization of Tlando in the US; Share..
MT
10/18ANTARES PHARMA : Strikes Exclusive License Agreement For Oral Testosterone Replacement The..
MT
10/18ANTARES PHARMA : ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH LIPOCINE FOR TLANDO® IN U.S ..
PU
10/18ANTARES PHARMA, INC. : Other Events (form 8-K)
AQ
10/18ANTARES PHARMA : Enters into Exclusive License Agreement With Lipocine for TLANDO® in U.S.
GL
10/18Antares Pharma Enters into Exclusive License Agreement with Lipocine for Tlando® in U.S
CI
09/30ANTARES PHARMA : Starts Phase 1 Study of ATRS-1902 Drug for Acute Adrenal Insufficiency Tr..
MT
09/30ANTARES PHARMA : Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
AQ
More news
Analyst Recommendations on ANTARES PHARMA, INC.
More recommendations